Actively Recruiting

Phase Not Applicable
Age: 18Years - 70Years
MALE
Healthy Volunteers
NCT06751862

The Role of Sugars in Fat Accumulation in the Liver

Led by Institute for Clinical and Experimental Medicine · Updated on 2024-12-30

40

Participants Needed

1

Research Sites

140 weeks

Total Duration

On this page

Sponsors

I

Institute for Clinical and Experimental Medicine

Lead Sponsor

C

Czech Health Research Council

Collaborating Sponsor

AI-Summary

What this Trial Is About

This interventional study has 2 parts. In the part A of the project, we will determine how the acute changes in hepatic fat content (HFC) after high-fat load (150 g of fat) are affected by co-administration with three doses of glucose, fructose, and sucrose. HFC in non-obese and obese male volunteers will be measured by magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) before and at the end of 6-hour intervention. The changes in triglycerides (TG), non-esterified fatty acids (NEFA), insulin and glucose will be also measured throughout the experiments. It can be expected that most of the obese subjects will also have a non-alcoholic fatty liver disease (NAFLD) and we will be therefore able to compare the HFC response between subjects with normal liver fat content and those with steatosis. Our previous results (doi: 10.26402/jpp.2021.1.05) clearly pointed out that glucose, contrary to fructose, prevents the storage of fat in the liver and that such an effect could be observed even after six hours. In the part B, we will therefore eliminate fructose from the diet of subjects with NAFLD of steatosis grade 2 for seven days - such an intervention will be isocaloric and fructose/sucrose will be replaced by starch or by glucose. The HFC content will be measured again by MRS and MRI after 168 hours. Very low density lipoprotein (VLDL), that transport TG out from the liver, will be isolated before and after intervention from the plasma obtained after overnight fasting. The analysis of lipid profile of the liver fat by MRS and fatty acid profile of TG in VLDL should provide an information on the role of de novo lipogenesis (DNL) in changes of HFC. In the part A of the project we will aim * to compare the response of HFC after high-fat load to repeated doses of glucose, fructose, and sucrose (3 x 50 g in two-hour intervals) * to compare such a response between non-obese and obese-subjects In the part B of the project we will aim * to find out whether short-term (7 days) restriction of fructose from the diet will decrease HFC in subjects with NAFLD * to find out whether such an intervention affects fatty acid profile of hepatic TG evaluated by MRS and by fatty acid profile of TG in VLDL - in this way we can estimate whether DNL is suppressed after fructose withdrawal * to further corroborate such an aim, we will also compare the fatty acid profile of plasma NEFA and that of TG in VLDL

CONDITIONS

Official Title

The Role of Sugars in Fat Accumulation in the Liver

Who Can Participate

Age: 18Years - 70Years
MALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Male volunteers aged 18 to 70 years
  • For Part A: 15 non-obese subjects with BMI less than 30 kg/m2 and 15 obese subjects with BMI 30 kg/m2 or higher
  • For Part B: Male volunteers with hepatic fat content between 6.2% and 16.5% (steatosis grade 2)
Not Eligible

You will not qualify if you...

  • Diabetes mellitus (fasting glucose above 7 mmol/l, 2-hour glucose after oral glucose tolerance test above 11.1 mmol/l, or receiving antidiabetic treatment)
  • Serious illnesses such as cardiovascular disease or cancer
  • Alcohol consumption of 30 grams or more per day
  • Fructose intolerance (Part A only)
  • Use of drugs affecting lipid metabolism
  • Intolerance of magnetic resonance examination (claustrophobia, metal implants, etc., Part B only)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Institute for Clinical and Experimental Medicine

Prague, Czech Republic, Czechia, 14021

Actively Recruiting

Loading map...

Research Team

J

Jan Kovář, PhD

CONTACT

D

Dita Pajuelo, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

PREVENTION

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here